ArticleJournal of medical biochemistry2026
Predictive value of TRIB3 combined with BMPR2 for major adverse cardiovascular events in elderly coronary heart disease patients undergoing percutaneous coronary intervention.
Article in Journal of medical biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This research aims to explore the correlation of Tribbles Pseudo kinase 3 (TRIB3) and bone morphogenetic protein receptor type 2 (BMPR2) with coronary heart disease (CHD), as well as the evaluation value of the combined detection of the two for major adverse cardiovascular events (MACE) following percutaneous coronary intervention (PCI). Methods: The study enrolled 152 CHD patients (CHD group) who underwent PCI treatment between January 2023 and May 2024 and 136 healthy individuals (control group) who concurrently underwent physical examination in our hospital. The expressions of TRIB3 and BMPR2 in the serum of both groups were measured. The clinical implications of these two factors in CHD and their diagnostic value for CHD were then analysed. Subsequently, the CHD patients were subjected to a 6-month follow-up. During this period, the occurrence of MACE was recorded, and the evaluation value of the combined detection of TRIB3 and BMPR2 for MACE was analysed. Results: In the CHD group, the concentration of TRIB3 was significantly elevated compared to the control group, with a notable decline in TRIB3 levels after treatment (P< 0.05). In contrast, the level of BMPR2 in the CHD group was significantly lower than that of the control group, and it increased substantially following treatment (P< 0.05). In the CHD group, TRIB3 and BMPR2 were closely correlated with cardiac troponin I (cTnI) and left ventricular ejection fraction (LVEF) (P< 0.05). The combined detection of TRIB3 and BMPR2 had a diagnostic sensitivity of 76.32% and a specificity of 91.18% for CHD (P< 0.05). The follow-up results showed that 25 patients experienced MACE. The diagnostic sensitivity and specificity of the combined detection of TRIB3 and BMPR2 for MACE were 60.00% and 90.55% , respectively (P< 0.05). Conclusions: TRIB3 and BMPR2 demonstrated excellent evaluation effects on CHD and the incidence of MACE after PCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.